Validation of a new cancer-related VTE model

Published Date: 02 Mar 2023

The ONKOTEV score predicts the risk of venous thromboembolism in cancer patients.

Read Full News

Latest News

BEACON: Positive Results Announced for Briquilimab in Chronic Spontaneous Urticaria

BEACON: Positive Results Announced for Briquilimab in Chronic Spontaneous Urticaria

Family Quality of Life Burden in CSU Increased by Lack of Disease Control

Family Quality of Life Burden in CSU Increased by Lack of Disease Control

Upadacitinib Superior to 4 Other JAKi Monotherapies for Atopic Dermatitis

Upadacitinib Superior to 4 Other JAKi Monotherapies for Atopic Dermatitis

Q4 2025 Recap: Dermatology News and Updates

Q4 2025 Recap: Dermatology News and Updates

Racial Disparities in Persistent Chemotherapy-Induced Alopecia Observed in Women

Racial Disparities in Persistent Chemotherapy-Induced Alopecia Observed in Women

6 Dermatology Headlines You Missed in December 2025

6 Dermatology Headlines You Missed in December 2025

Todays Updates

Combination Navepegritide, Lonapegsomatropin Shows Durable Benefit in Phase 2 Pediatric Achondroplasia Trial

Combination Navepegritide, Lonapegsomatropin Shows Durable Benefit in Phase 2 Pediatric Achondroplasia Trial

Todays Updates

Combination Navepegritide, Lonapegsomatropin Shows Durable Benefit in Phase 2 Pediatric Achondroplasia Trial

Combination Navepegritide, Lonapegsomatropin Shows Durable Benefit in Phase 2 Pediatric Achondroplasia Trial

Latest News

BEACON: Positive Results Announced for Briquilimab in Chronic Spontaneous Urticaria

Family Quality of Life Burden in CSU Increased by Lack of Disease Control

Upadacitinib Superior to 4 Other JAKi Monotherapies for Atopic Dermatitis

Q4 2025 Recap: Dermatology News and Updates

Racial Disparities in Persistent Chemotherapy-Induced Alopecia Observed in Women

6 Dermatology Headlines You Missed in December 2025

News All Time

Nemolizumab Rapidly Relieves Itch in Atopic Dermatitis, Prurigo Nodularis

Nemolizumab Rapidly Relieves Itch in Atopic Dermatitis, Prurigo Nodularis

Phase 3 SCALP Study on Clascoterone for Androgenetic Alopecia, With Maria Hordinsky, MD

Phase 3 SCALP Study on Clascoterone for Androgenetic Alopecia, With Maria Hordinsky, MD

Vixarelimab Demonstrates Rapid, Sustained Clinical Benefits in Prurigo Nodularis

Vixarelimab Demonstrates Rapid, Sustained Clinical Benefits in Prurigo Nodularis

Once-Daily Oral Zasocitinib Delivers Strong Phase 3 Efficacy in Plaque Psoriasis

Once-Daily Oral Zasocitinib Delivers Strong Phase 3 Efficacy in Plaque Psoriasis

REZOLVE-AA: Phase 2b Data Released on Rezpegaldesleukin for Alopecia Areata

REZOLVE-AA: Phase 2b Data Released on Rezpegaldesleukin for Alopecia Areata

Special Report: Reframing Skin Pain in Atopic Dermatitis Mona Shahriari, MD, FAAD, Andrew Mastro, MS, PA-C

This video explores skin pain as a key symptom of atopic dermatitis and reviews clinical trial data with JAK inhibitors.

Skin of Color Savvy: Winter Skin Care for Patients of Color, With Heather Woolery-Lloyd, MD, and Aderonke Obayomi, MD, MPH

Skin of Color Savvy: Winter Skin Care for Patients of Color, With Heather Woolery-Lloyd, MD, and Aderonke Obayomi, MD, MPH

Addictive Behaviors Linked with Chronic Skin Diseases Such as HS, Psoriasis

Addictive Behaviors Linked with Chronic Skin Diseases Such as HS, Psoriasis

Prurigo Nodularis Linked to Increased Risk of Malignancy, Especially Skin Cancers

Prurigo Nodularis Linked to Increased Risk of Malignancy, Especially Skin Cancers

Imsidolimab’s Biologics License Application for Treatment of GPP Submitted to FDA

Imsidolimab’s Biologics License Application for Treatment of GPP Submitted to FDA

Dupilumab Shows Greatest Rate of 2-Year Drug Survival Among Atopic Dermatitis Drugs

Dupilumab Shows Greatest Rate of 2-Year Drug Survival Among Atopic Dermatitis Drugs

Tips on Patient Communication in Dermatology, With Kassandra Holzem, MD Kassandra Holzem, MD

Holzem spoke in this interview about several additional highlights from her session at SDPA Fall regarding red flags in dermatology and when to admit from the clinic.

Key Skin Cancer Terms Not Understood by Almost 1/3 of Patients Surveyed

Key Skin Cancer Terms Not Understood by Almost 1/3 of Patients Surveyed

FDA Proposes Expanding Active Ingredient List for Sunscreens

FDA Proposes Expanding Active Ingredient List for Sunscreens

Apremilast Effective Treatment for Moderate to Severe Genital Psoriasis at 32 Weeks

Apremilast Effective Treatment for Moderate to Severe Genital Psoriasis at 32 Weeks

Mild to Moderate Psoriasis Linked with Indicators of Suboptimal Treatment, Disease Control

Mild to Moderate Psoriasis Linked with Indicators of Suboptimal Treatment, Disease Control

Recommended News For You

Medical debt in collections persists after cancer diagnosis

Through Consolidation Durvalumab, Limited-Stage SCLC Receives a New Standard of Care.

Exercise could ease symptoms for people with chronic lymphocytic leukemia, support and guidance are lacking: Study

Screening for prostate cancer: is it time to give up digital rectal examination?

Liquid Biopsy for Colorectal Cancer Screening Might Not Be Ready for Prime Time.

Teenagers Frequently Use Delta-8 THC; New Drug-Coated Balloon Treats Blocked Stents.

Multidrug Regimen Could Change Treatment Landscape for Relapsed/Refractory DLBCL

Recommended Articles For You

Unlocking the Mysteries of Rhabdomyoma: A New Hope for Treatment 

Decoding Efficacy, Safety, and Future Frontiers in CAR-T Cell Therapy for Hematologic Malignancies Towards CAR-T Therapy 2025 

The Expanding Horizon of PSMA: A Comparative Clinical Review of Theranostics in Prostate Cancer and Beyond 

Introducing the Corrected Calcium Calculator: A Revolutionary Tool in Medical Assessment  

Whats more on Hidoc Dr.

Medical Updates
KOL Videos
Surveys
Events

Daily news to keep you up to date

Gain valuable insights with our in-depth KOL Video discussions

Participate and win cash vouchers

Get updates on the latest events happening around the world
Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Lesser-known lobular breast cancer on the rise in U.S. women

2.

For patients with breast cancer receiving chemotherapy, exercise may help lessen the long-term side effects.

3.

PET-CT is better than contrast-enhanced CT as a predictor of survival in patients with metastatic breast cancer

4.

King Charles' Cancer; COVID Vax Now or Later; Was RFK Jr. a Drug Dealer?

5.

Study sets benchmark for treatment of advanced cervical cancer

1.

How Prevident is Revolutionizing Oral Care

2.

Multimodal Data Fusion with Deep Neural Networks - Revolutionizing Oncology with Precision Cancer Diagnosis 2025

3.

Prognostic Role of PLAU in Pan-Cancer and Neutrophil Infiltration in Bladder Cancer

4.

Precision Oncology Advances: Neoantigen Therapies, TCR Strategies & Radiotherapy Innovations

5.

Introduction to Immune Thrombocytopenic Purpura

1.

International Lung Cancer Congress®

2.

Genito-Urinary Oncology Summit 2026

3.

Future NRG Oncology Meeting

4.

ISMB 2026 (Intelligent Systems for Molecular Biology)

5.

Annual International Congress on the Future of Breast Cancer East

1.

Efficient Management of First line ALK-rearranged NSCLC - Part V

2.

Influence of CDK4/6 Inhibitors in Extending Progression-Free Survival (PFS) and Overall Survival in HR+/HER2- mBC Patients

3.

Redefining Treatment Pathways in Relapsed/Refractory Adult B-Cell ALL

4.

Virtual Case Study on Pedal Edema and Triple Vessel Disease - An Initiative by Hidoc Dr.

5.

Efficient Management of First line ALK-rearranged NSCLC - Part VIII

Fastest Growing Medical Platform for Doctors

Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801

Phone :
+1-415-463-3094

Email :
anishagadia@hidoc.co

Quick Links

Drug DatabaseDrug InteractionDiseases Database
KOL VideosKnowledge HubQuizzes
Medical UpdatesEventsAbout Us

© Copyright 2025 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
Home
Profile
Login
bot